|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Fondaparinux#Drug Interactions]] |
| {{Fondaparinux}}
| |
| {{CMG}}; {{AE}} {{AZ}}
| |
|
| |
|
| ==Drug Interactions==
| | [[Category: Cardiovascular Drugs]] |
| n clinical studies performed with ARIXTRA, the concomitant use of oral [[anticoagulants ]]([[warfarin]]), platelet inhibitors ([[acetylsalicylic acid]]), [[NSAIDs]]([[piroxicam]]), and [[digoxin ]]did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium. In addition, ARIXTRA neither influenced the pharmacodynamics of [[warfarin]], [[acetylsalicylic acid]], [[piroxicam]], and [[digoxin]], nor the pharmacokinetics of digoxin at steady state.
| | [[Category: Drug]] |
| | | [[Category: Anticoagulants]] |
| Agents that may enhance the risk of hemorrhage should be discontinued prior to initiation of therapy with ARIXTRA unless these agents are essential. If co-administration is necessary, monitor patients closely for hemorrhage. [See [[Fondaparinux warnings and precautions|Warnings and Precautions (5.1)]].]
| |
| In an in vitro study in human liver microsomes, inhibition of CYP2A6 hydroxylation of [[coumarin]] by fondaparinux (200 micromolar i.e., 350 mg/L) was 17 to 28%. Inhibition of the other isozymes evaluated (CYPs 1A2, 2C9, 2C19, 2D6, 3A4, and 3E1) was 0 to 16%. Since fondaparinux does not markedly inhibit CYP450s (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4) in vitro, fondaparinux sodium is not expected to significantly interact with other drugs in vivo by inhibition of metabolism mediated by these isozymes.
| |
| | |
| Since fondaparinux sodium does not bind significantly to plasma proteins other than [[antithrombin|ATIII]], no drug interactions by protein-binding displacement are expected.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ARIXTRA (FONDAPARINUX SODIUM) INJECTION, SOLUTION [GLAXOSMITHKLINE LLC] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=05bb2dd4-5fb5-4ec9-29a8-d200e62d1a8f | publisher = | date = | accessdate = }}</ref>
| |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| [[Category:Cardiovascular Drugs]] | |
| [[Category:Drugs]] | |